Crescendo Biologics, Takeda deal

Crescendo will use its transgenic mouse platform to discover and optimize Humabodies against undisclosed targets selected by Takeda. Humabodies are based on human variable antibody fragments. The companies said the deal is focused on generating tumor-targeting drug conjugates and immuno-oncology therapeutics. Takeda will be responsible for developing and commercializing Humabody-based therapeutics resulting from the deal. ...